

**Table 1.** Patient characteristics at trial randomization and RRT initiation before and after overlap weighting.

Characteristics	Crude			Overlap weights		
	CRRT (n=1590)	IHD (n=606)	SD	CRRT (n=1590)*	IHD (n=606)*	SD
Age, years	63.7 (14.3)	65.9 (13.4)	-0.16	65.5 (13.8)	65.4 (13.4)	0.00
Body weight, kg	87.6 (26.4)	87.7 (25.1)	0.00	86.8 (25.9)	87.0 (24.9)	-0.01
Female sex	508 (31.9)	189 (31.2)	-0.02	506 (31.8)	192 (31.7)	0.01
Baseline serum creatinine, mg/dl	1.3 (1.0)	1.4 (1.1)	-0.11	1.4 (1.2)	1.4 (1.1)	0.00
Baseline GFR, ml/min/1.73 m <sup>2</sup>	67.8 (30.0)	63.6 (29.9)	0.14	64.8 (30.3)	64.8 (30.0)	0.00
<b>Pre-existing conditions</b>						
Chronic kidney disease	667 (41.9)	295 (48.7)	-0.14	737 (46.4)	282 (46.6)	0.00
Hypertension	859 (54.0)	357 (58.9)	-0.10	912 (57.4)	348 (57.4)	0.00
Diabetes mellitus	470 (29.6)	195 (32.2)	-0.06	495 (31.1)	189 (31.2)	0.00
Heart failure	198 (12.5)	96 (15.8)	-0.10	230 (14.5)	88 (14.5)	0.00
Liver disease	200 (12.6)	63 (10.4)	0.07	176 (11.1)	68 (11.2)	0.00
<b>Characteristics at randomization</b>						
SOFA score	12.2 (3.5)	11.4 (3.6)	0.21	12.2 (3.3)	12.2 (3.3)	-0.01
SAPS II score	60.7 (17.2)	57.2 (16.9)	0.20	58.1 (16.7)	58.1 (17.1)	0.00
Serum creatinine, mg/dl	3.4 (1.7)	4.0 (1.7)	-0.33	3.8 (2.0)	3.8 (1.7)	0.00
Hemoglobin, g/L	99.8 (22.9)	98.6 (24.1)	0.05	99.4 (23.0)	99.3 (24.6)	0.00
Serum urea, mmol/L	20.3 (10.7)	23.4 (11.6)	-0.27	22.8 (11.8)	22.7 (11.3)	0.00
Cardiopulmonary bypass in preceding 7 days	140 (8.8)	30 (5.0)	0.15	96 (6.0)	36 (5.9)	0.00
Aortic aneurysm repair in preceding 7 days	86 (5.4)	21 (3.5)	0.09	60 (3.8)	23 (3.8)	0.00
Other vascular surgery in preceding 7 days	83 (5.2)	30 (5.0)	0.01	81 (5.1)	31 (5.1)	0.00
Trauma in preceding 7 days	63 (4.0)	24 (4.0)	0.00	59 (3.7)	23 (3.8)	0.00
Sepsis in the last 72 hours	922 (58.0)	374 (61.7)	-0.08	954 (60.0)	364 (60.1)	0.00
Mechanical ventilation	1275 (80.2)	447 (73.8)	0.15	1187 (74.7)	452 (74.6)	0.00
Vasoactive medication	1224 (77.0)	347 (57.3)	0.43	1013 (63.7)	386 (63.7)	0.00
Cumulative fluid balance at randomization, mL	4054.5 (5766.0)	4811.2 (6535.3)	-0.11	4441.8 (7085.3)	4446.8 (6063.1)	0.00
<b>Characteristics at RRT initiation</b>						
Time from ICU admission to RRT initiation, hours	96.0 (289.9)	111.5 (170.7)	-0.07	108.6 (342.6)	106.8 (179.6)	0.01
Days from hospital admission to RRT initiation	8.9 (16.3)	9.7 (13.5)	-0.06	9.7 (18.9)	9.6 (14.1)	0.00
SOFA score components						
- Respiratory	2.2 (1.1)	1.9 (1.1)	0.26	2.5 (1.2)	2.5 (1.2)	-0.01
- Coagulation	1.1 (1.1)	0.9 (1.1)	0.11	1.1 (1.3)	1.1 (1.3)	0.00

- Liver	0.9 (1.1)	0.7 (1.1)	0.13	0.7 (1.1)	0.7 (1.1)	-0.01
- Cardiovascular	2.6 (1.6)	1.8 (1.8)	0.47	1.2 (1.2)	1.1 (1.1)	0.00
- Central nervous system	2.3 (1.6)	1.8 (1.6)	0.33	1.1 (1.2)	1.3 (1.3)	0.00
- Renal	2.8 (0.9)	3.2 (0.8)	-0.46	1.1 (1.2)	1.1 (1.2)	-0.01
Total SOFA score	11.8 (3.6)	10.4 (3.6)	0.41	10.8 (3.6)	10.8 (3.6)	-0.01
Urine output in preceding 24 hours	804.3 (990.5)	649.4 (813.7)	0.17	696.6 (823.0)	689.9 (850.4)	0.01
Cumulative fluid balance at RRT initiation	4873.9 (6417.9)	6574.1 (8403.1)	-0.22	5633.7 (7915.8)	5654.1 (7025.4)	0.00
Serum creatinine, mg/dL	3.9 (1.9)	4.7 (2.1)	-0.42	4.4 (2.2)	4.4 (2.0)	0.00
Serum urea, mmol/L	23.9 (18.9)	27.4 (13.8)	-0.23	26.1 (21.2)	26.1 (15.0)	0.00
Serum potassium, mmol/L	4.5 (0.7)	4.4 (0.7)	0.14	4.4 (0.7)	4.4 (0.7)	0.01
Bicarbonate, mmol/L	20.2 (4.7)	20.0 (4.1)	0.05	20.0 (4.7)	20.0 (4.2)	0.00
pH at RRT initiation	7.3 (0.1)	7.3 (0.1)	-0.03	7.3 (0.1)	7.3 (0.1)	0.00
Hemoglobin, g/L	97.4 (33.3)	95.8 (21.7)	0.06	96.7 (25.7)	96.6 (22.6)	0.00

Continuous variables expressed as mean (standard deviation); categorical variables expressed as number (%)

§ Vasoactive support was defined as receipt of any dose of norepinephrine, epinephrine, vasopressin, levosimendan, dobutamine, milrinone, or phenylephrine.

\*All patients were included in the analyses using overlap weighting. The number of observations in the pseudo-population based on overlap weighting was 373 in the CRRT group and 373 in the IHD group.

SD, standardized difference; RRT, renal replacement therapy; CRRT, continuous renal replacement therapy; IHD, intermittent hemodialysis; GFR, glomerular filtration rate; SOFA, Sequential Organ Failure Assessment; SAPS, Sepsis Acute Physiology Score; ICU, intensive care unit

**Table 2.** The association between initial RRT modality and primary and secondary outcomes

	Number of patients available for analysis				OR or MD Overlap weighting (95% CI)	p-value
	CRRT	IHD	CRRT	IHD		
<b>Primary Outcome</b>						
Death or RRT dependence at 90-days, n (%)	1590	606	823 (51.8)	329 (54.3)	0.81 (0.66 to 0.99)	0.044
<b>Secondary Outcomes</b>						
All-cause mortality at 90 days, n (%)	1590	606	752 (47.3)	279 (46.0)	0.90 (0.74 to 1.11)	--
RRT dependence at 90 days (survivors only), (n (%))	838	327	71 (8.4)	50 (15.2)	0.61 (0.39 to 0.94)	--
ICU length of stay, days	1590	606	12 (5 to 36)	17 (7 to 165)	-16.8 (-34.3 to 0.7)	--
Hospital length of stay, days	1590	606	27 (10 to 81)	40 (15 to 166)	-14.8 (-32.0 to 2.5)	--
ICU-free days at 28 days, median (IQR)	1590	606	0 (0 to 17)	0 (0 to 17)	2.0 (1.0 to 3.0)	--
Hospital-free days at 90 days, median (IQR)	1590	606	0 (0 to 56)	0 (0 to 41)	6.6 (3.1 to 10.0)	--
Ventilator-free days at 28 days, median (IQR)	1590	606	15 (0 to 23)	17 (0 to 25)	0.4 (-0.8 to 1.6)	--
Vasoactive-free days at Day 28, median (IQR)	1590	606	20 (0 to 25)	24 (0 to 27)	-0.7 (-1.9 to 0.5)	--

RRT, renal replacement therapy ;CRRT, continuous renal replacement therapy; IHD, intermittent hemodialysis; ICU, intensive care unit; OR, odds ratio; MD, mean difference